{"filing":{"accession_number":"0000105770-26-000093","cik":"0000105770","ticker":"WST","company_name":"WEST PHARMACEUTICAL SERVICES INC","form":"8-K","filing_date":"2026-07-14","report_date":null,"primary_document":"wst-20260714.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/105770/000010577026000093/wst-20260714.htm"},"events":[{"id":17877,"run_id":16036,"accession_number":"0000105770-26-000093","anchor_item_number":"1.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"West Pharmaceutical entered into amended and restated technology exchange, cross-license, and distributorship agreements with Daikyo Seiko, Ltd. effective July 14, 2026. These are material commercial agreements governing technology sharing, licensing rights, and distribution arrangements for pharmaceutical packaging products with a 10-year term. While the agreements are substantially similar to prior versions, the formal amendment and restatement of these foundational commercial relationships constitutes a material operational event that does not fit the specific categories of M\u0026A activity, debt issuance, or other defined financial/legal events.","company_name":"WEST PHARMACEUTICAL SERVICES INC","ticker":"WST","filing_date":"2026-07-14","form":"8-K","submitted_at":null,"items":[{"id":16507,"accession_number":"0000105770-26-000093","item_number":"1.01","item_title":"Entry Into a Material Definitive Agreement.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"West Pharmaceutical entered into amended and restated technology exchange, cross-license, and distributorship agreements with Daikyo Seiko, Ltd. effective July 14, 2026. These are material commercial agreements governing technology sharing, licensing rights, and distribution arrangements for pharmaceutical packaging products with a 10-year term. While the agreements are substantially similar to prior versions, the formal amendment and restatement of these foundational commercial relationships constitutes a material operational event that does not fit the specific categories of M\u0026A activity, debt issuance, or other defined financial/legal events.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-14T20:30:36.751942+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":16507,"accession_number":"0000105770-26-000093","item_number":"1.01","item_title":"Entry Into a Material Definitive Agreement.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"West Pharmaceutical entered into amended and restated technology exchange, cross-license, and distributorship agreements with Daikyo Seiko, Ltd. effective July 14, 2026. These are material commercial agreements governing technology sharing, licensing rights, and distribution arrangements for pharmaceutical packaging products with a 10-year term. While the agreements are substantially similar to prior versions, the formal amendment and restatement of these foundational commercial relationships constitutes a material operational event that does not fit the specific categories of M\u0026A activity, debt issuance, or other defined financial/legal events.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-14T20:30:36.751942+00:00","company_name":"WEST PHARMACEUTICAL SERVICES INC","ticker":"WST","filing_date":"2026-07-14"}]}